SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Pfizer launches new medication for migraine treatment

17 Nov 2025 Evaluate

Pfizer has launched a new medication for migraine treatment. The company has introduced Rimegepant ODT in India for adults with a previous insufficient response to triptan, the usual drugs for treating migraine.

The new medication delivers rapid and sustained pain relief lasting up to 48 hours post-treatment, while not associated with the risk of medication overuse headaches. Rimegepant will be available in a 75 mg orally disintegrating tablet (ODT) form, designed for convenient administration without the need for water.

Pfizer is engaged in manufacturing, marketing, trading and export of pharmaceutical products.

Pfizer Share Price

4432.85 13.00 (0.29%)
05-Jun-2026 11:03 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1793.00
Dr. Reddys Lab 1277.05
Cipla 1388.10
Zydus Lifesciences 1089.75
Lupin 2272.30
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×